Paper Finds Microdroplet PCR Enrichment Ideal Targeted Sequencing Solution for Large-Scale Population Studies
News Nov 05, 2009
Data generated using microdroplet PCR technology as an enrichment method is particularly well suited for performing sequence-based association studies, according to a paper published by researchers at the Scripps Translational Science Institute, the University of California, San Diego School of Medicine, and RainDance Technologies, Inc.
The study, led by Kelly A. Frazer, Ph.D., Professor of Pediatrics and Chief, Division of Genome Information Sciences, UC San Diego Department of Pediatrics, evaluated microdroplet PCR’s advantages in performing sequence enrichment for targeted sequencing over the gold-standard traditional PCR approach. “These benefits translated into a much higher efficiency of sequencing and a much more cost-effective way to do population studies,” Frazer said, in commenting about the paper.
Entitled “Microdroplet-based PCR Enrichment for Large-Scale Targeted Sequencing,” the paper was published on Nature Biotechnology’s Web site at Microdroplet-based PCR enrichment for large-scale targeted sequencing and will appear in the November issue of the magazine.
“I believe this new technology will be used to study the basic underpinnings of diseases and to understand their root causes,” said Eric J. Topol, M.D., Director of the Scripps Translational Science Institute and a co-author. “For instance, we’re now using it to understand the causes of anorexia nervosa. We also can use the technology to comprehend a disease’s response to a therapy or to determine a drug’s side effects. We even can employ it to study the healthy aging process. These are all applications for microdroplet PCR that will help us understand the vital aspects of human health and disease,” said Dr. Topol, in commenting on the paper.
The paper said that to efficiently perform population-based sequencing studies using next-generation sequencing platforms, it is important to be able to simultaneously examine large numbers of targeted sequences. “These results indicate that even when simultaneously amplifying 3,976 targeted sequences, microdroplet PCR generates a high ratio of target sequence to background sequence,” the authors said. The study concluded that data quality is independent of the number of amplicons. A path to scale to 20,000 amplicons while maintaining high performance was also demonstrated.
The paper’s authors said the microdroplet PCR process proved to be efficient, with more than 99.6% of all amplicons being successful and with highly reproducible amplification of targeted sequences between samples. The data also showed that equivalently accurate SNP calling can be performed using microdroplet PCR whether the DNA is unamplified or whole-genome amplified from nanogram quantities. The allelic bias error rate of approximately 0.1% resulted in few known variants to be incorrectly called, further attesting to the robustness of the process.
“We were impressed with how well the technology worked,” said Dr. Frazer. “Compared to other types of sequence enrichment, we were able to generate greater uniform coverage of targeted sequences. In addition, the problems we typically encounter with standard PCR, such as difficult primer design and high allelic bias, were not observed with the microdroplet-based PCR workflow.”
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018